Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
Recruiting · NCT06488222 · Registry updated 2026-03-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-03-11 | NCT06488222 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Florida | 315 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Florida | Gainesville | United States | 70 |